SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for non-surgical weight loss, announces it has treated the first patients at its Company-owned weight loss treatment center, the Obalon Center for Weight Loss, in San Diego, California.
”We are very pleased to commence operations at the Obalon Center for Weight Loss,” said William Plovanic, President and Chief Financial Officer. “We opened this direct channel to treat patients in order to improve outcomes and the access and affordability for patients with obesity seeking to lose weight with the Obalon Balloon System. We invented, developed, manufactured, and now are facilitating delivery of this important therapy with the Obalon Balloon directly to patients.”
The Obalon Center for Weight Loss is a medical facility staffed with physicians specializing in weight loss, nutritional counselors to help patients change their eating habits for sustainable weight loss, and other staff to help provide safe and effective treatment with the Obalon Balloon System.
Dr. Rita Starritt, a treating physician at the Obalon Center for Weight Loss, said, “I am very pleased to be part of the first Obalon Center for Weight Loss. There are so many patients with obesity who want to lose weight but are frustrated by and have failed conventional diet and exercise programs. The Obalon Balloon System is an FDA-approved, scientifically proven, non-surgical weight loss solution for people who are approximately 30 to 100 pounds overweight or have a BMI between 30 and 40. Published results from clinical trials supporting FDA approval showed a strong safety profile and demonstrated that patients receiving the Obalon Balloon System had twice as much weight loss than patients who received a placebo device with diet and exercise therapy.”
The Company expects to provide more information on the treatment center strategy in November when it reports third quarter financial results for the quarter ending September 30, 2019.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit www.obalon.com.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Obalon Therapeutics, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Obalon Therapeutics' future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Obalon Therapeutics undertakes no obligation to update or revise any forward-looking statements. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Obalon Therapeutics' business in general, please refer to Obalon Therapeutics’ annual report on Form 10-K filed with the Securities and Exchange Commission on February 22, 2019, Form 10-Q filed with the Securities and Exchange Commission on July 24, 2019, and its future periodic reports filed with the Securities and Exchange Commission.
For Obalon Therapeutics, Inc.
President & Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103